TransMedics Valuation
| TMDX Stock | USD 87.11 6.50 8.06% |
At this time, the company appears to be overvalued. TransMedics Group has a current Real Value of $78.4 per share. The regular price of the company is $87.11. Our model measures the value of TransMedics Group from inspecting the company fundamentals such as Shares Outstanding of 33.56 M, operating margin of 0.04 %, and Return On Equity of 0.19 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting TransMedics' valuation include:
Price Book 13.9269 | Enterprise Value 3.1 B | Enterprise Value Ebitda 48.0333 | Price Sales 7.289 | Forward PE 63.2911 |
Overvalued
Today
Please note that TransMedics' price fluctuation is very steady at this time. Calculation of the real value of TransMedics Group is based on 3 months time horizon. Increasing TransMedics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since TransMedics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of TransMedics Stock. However, TransMedics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 87.11 | Real 78.4 | Target 87.75 | Hype 87.11 | Naive 88.49 |
The intrinsic value of TransMedics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence TransMedics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of TransMedics Group helps investors to forecast how TransMedics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of TransMedics more accurately as focusing exclusively on TransMedics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use TransMedics' intrinsic value based on its ongoing forecasts of TransMedics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against TransMedics' closest peers.
TransMedics Cash |
|
TransMedics Valuation Trend
Analysing the historical paterns of TransMedics' enterprise value and its market capitalization is a good way to estimate and gauge the value of TransMedics Group over time and is usually enough for investors to make rational market timing decisions.
TransMedics Revenue by Product
TransMedics Total Value Analysis
TransMedics Group is at this time forecasted to have valuation of 3.11 B with market capitalization of 2.92 B, debt of 515.95 M, and cash on hands of 204.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the TransMedics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.11 B | 2.92 B | 515.95 M | 204.46 M |
TransMedics Investor Information
About 97.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Based on the key indicators related to TransMedics' liquidity, profitability, solvency, and operating efficiency, TransMedics Group is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.TransMedics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. TransMedics has an asset utilization ratio of 34.22 percent. This suggests that the Company is making $0.34 for each dollar of assets. An increasing asset utilization means that TransMedics Group is more efficient with each dollar of assets it utilizes for everyday operations.TransMedics Ownership Allocation
The majority of TransMedics Group outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in TransMedics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in TransMedics Group. Please pay attention to any change in the institutional holdings of TransMedics Group as this could imply that something significant has changed or is about to change at the company.TransMedics Profitability Analysis
The company reported the previous year's revenue of 241.62 M. Net Loss for the year was (25.03 M) with profit before overhead, payroll, taxes, and interest of 65.27 M.About TransMedics Valuation
Our relative valuation model uses a comparative analysis of TransMedics. We calculate exposure to TransMedics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of TransMedics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 154.1 M | 161.8 M | |
| Pretax Profit Margin | (0.11) | (0.12) | |
| Operating Profit Margin | (0.12) | (0.12) | |
| Net Loss | (0.10) | (0.11) | |
| Gross Profit Margin | 0.64 | 0.41 |
TransMedics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 32.5 M | |
| Forward Price Earnings | 63.2911 |
TransMedics Current Valuation Indicators
Valuation refers to the process of determining the present value of TransMedics Group and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value TransMedics we look at many different elements of the entity such as TransMedics's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as TransMedics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use TransMedics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes TransMedics' worth.Additional Tools for TransMedics Stock Analysis
When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.